24/7 Market News Snapshot 27 February, 2025 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)

February 27, 2025

DENVER, Colo., 27 February, 2025 (247marketnews.com) – (NASDAQ:TLSA) are discussed in this article.
Tiziana Life Sciences Ltd. (TLSA) is experiencing a noteworthy surge in market activity following the publication of a significant study demonstrating the effectiveness of its lead investigational candidate, intranasal foralumab. The stock opened robustly today at $1.02, reflecting a spectacular increase of 21.94%, and is currently trading at $1.195 with a trading volume of 1.52 million shares. This activity underscores the market’s enthusiastic response to the biopharmaceutical company’s innovative approaches.

The groundbreaking research, featured in the esteemed journal Nature Neuroscience, led by Dr. Saef Izzy, focuses on the potential of intranasal foralumab to effectively address traumatic brain injury (TBI). The study highlights how administering the fully human anti-CD3 monoclonal antibody nasally significantly mitigates neuroinflammation and enhances recovery outcomes in preclinical models. The findings demonstrate that this therapy promotes the generation of IL-10 producing regulatory T cells (Tregs), crucial for modulating microglial activity in the brain and leading to improved neurological outcomes, including diminished anxiety, cognitive decline, and enhanced motor skills.

Dr. Howard L. Weiner, Co-Director of the Ann Romney Center for Neurologic Diseases, praised the unique aspects of nasal delivery in combating neuroinflammation, emphasizing the transformative potential of immune modulation for improving recovery post-TBI. Tiziana’s commitment to advancing intranasal foralumab is further reflected in ongoing clinical trials targeting other neuroinflammatory conditions such as Multiple Sclerosis and Alzheimer’s disease, areas marked by substantial unmet medical needs.

CEO Ivor Elrifi articulated the company’s excitement regarding the potential impact of foralumab on TBI and other acute brain injuries, reinforcing Tiziana’s mission to revolutionize immunotherapy through advanced delivery technologies and improve treatment options for patients facing neurological disorders.

Related news for (TLSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.